Cipla Limited has notified stakeholders regarding the National Company Law Tribunal’s (NCLT) order on 18th August, 2026, approving the Scheme of Amalgamation with Inzpera Healthsciences Limited. While meetings for equity shareholders and unsecured creditors of Cipla have been dispensed with, they have 30 days from notice receipt to submit representations to the NCLT. The full scheme details are available on Cipla’s website.
Amalgamation Scheme Progress
Cipla Limited has officially informed its stakeholders about a significant development concerning its proposed Scheme of Amalgamation by Absorption of Inzpera Healthsciences Limited. This communication follows an order passed by the Hon’ble National Company Law Tribunal (NCLT), Mumbai Bench, on 18th August, 2026.
Shareholder and Creditor Notification
In compliance with the NCLT’s directive, Cipla is disseminating notices to its shareholders and creditors. These notices are being sent electronically where email addresses are available, and physically to the remaining stakeholders. The primary purpose is to inform them about the approved Scheme and to provide an opportunity to convey any representations or objections.
Representation Period
Shareholders and creditors have a window of 30 days from the date of receipt of the notice to submit their representations, if any, to the Hon’ble NCLT. A copy of these representations must also be sent simultaneously to Cipla’s Registered Office. The absence of any representation within this stipulated period will be presumed as no objection to the proposed Scheme of Amalgamation.
Access to Scheme Documents
Further details, including the notice under Section 230(5) of the Companies Act, 2013, the NCLT Order, and the full Scheme of Amalgamation, are accessible and downloadable from Cipla’s official website. This transparency ensures all stakeholders are well-informed about the process and its implications.
Source: BSE
